Literature DB >> 33910455

Promoting roles of KLF5 in myocardial infarction in mice involving microRNA-27a suppression and the following GFPT2/TGF-β/Smad2/3 axis activation.

Zhen Tian1, Yan Zhang2, Xueman Lyu3.   

Abstract

Myocardial infarction (MI) is a major atherosclerotic cardiovascular disease which represents a leading cause of death worldwide. Kruppel-like factor 5 (KLF5) is a member of the kruppel-like transcription factor family which has been reported with pro-apoptotic functions in myocardial cells. This work focuses on the function of KLF5 in the pathogenesis of MI and the molecules involved. A mouse model with MI was established. Hypoxia/reoxygenation (H/R)-treated H9C2 cells were applied for in vitro experiments. A KLF5-specific inhibitor ML264 was administrated in cell and animal models. ML264 significantly reduced apoptosis, expression of fibrosis-related markers, reactive oxygen species in the H/R-treated H9C2 cells, and it reduced myocardial injury, infarct size, apoptosis and fibrosis in the myocardial tissues in model mice through specific downregulation of KLF5. A microRNA (miRNA) microarray analysis was performed, which suggested miR-27a as the most upregulated miRNA in the H/R-treated cells after ML264 treatment. miR-27a mimic reduced apoptosis and fibrosis in H/R-treated cells, while miR-27a inhibition blocked the protective roles of ML264. The integrated bioinformatic analyses and luciferase assays confirmed glutamine fructose-6-phosphate transaminase 2 (GFPT2) mRNA as a target of miR-27a. Overexpression of GFPT2 counteracted the protective functions of miR-27a against MI through the activation of the TGF-β/Smad2/3 signaling pathway. To conclude, this study evidenced that KLF5 possibly induces cell and tissue damage in MI through downregulation of miR-27a and the subsequent activation of GFPT2/TGF-β/Smad2/3 axis. This study may offer novel thoughts into MI treatment.

Entities:  

Keywords:  GFPT2; KLF5; Myocardial infarction; TGF-β/Smad2/3 signaling pathway; miR-27a; myocardial fibrosis

Mesh:

Substances:

Year:  2021        PMID: 33910455      PMCID: PMC8168596          DOI: 10.1080/15384101.2021.1907512

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  34 in total

Review 1.  Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease.

Authors:  Simon Barquera; Andrea Pedroza-Tobías; Catalina Medina; Lucía Hernández-Barrera; Kirsten Bibbins-Domingo; Rafael Lozano; Andrew E Moran
Journal:  Arch Med Res       Date:  2015-06-29       Impact factor: 2.235

Review 2.  Mechanical, inflammatory, and embolic complications of myocardial infarction: An emergency medicine review.

Authors:  Tim Montrief; William T Davis; Alex Koyfman; Brit Long
Journal:  Am J Emerg Med       Date:  2019-04-08       Impact factor: 2.469

3.  Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes.

Authors:  Pushplata Prasad; Arun K Tiwari; K M Prasanna Kumar; A C Ammini; Arvind Gupta; Rajeev Gupta; B K Thelma
Journal:  BMC Med Genet       Date:  2010-03-31       Impact factor: 2.103

Review 4.  The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction.

Authors:  Samantha D Francis Stuart; Nicole M De Jesus; Merry L Lindsey; Crystal M Ripplinger
Journal:  J Mol Cell Cardiol       Date:  2015-12-29       Impact factor: 5.000

5.  Gualou Xiebai Decoction prevents myocardial fibrosis by blocking TGF-beta/Smad signalling.

Authors:  Yong-fang Ding; Yun-ru Peng; Juan Li; Hong Shen; Ming-qin Shen; Tai-hui Fang
Journal:  J Pharm Pharmacol       Date:  2013-07-10       Impact factor: 3.765

Review 6.  The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment.

Authors:  Sharareh Gholamin; Alireza Pasdar; Mohammad Sadegh Khorrami; Hamed Mirzaei; Hamid Reza Mirzaei; Rasoul Salehi; Gordon A Ferns; Majid Ghayour-Mobarhan; Amir Avan
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 7.  Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity.

Authors:  Peter James O'Brien
Journal:  Toxicology       Date:  2007-12-17       Impact factor: 4.221

8.  Osthole decreases collagen I/III contents and their ratio in TGF-β1-overexpressed mouse cardiac fibroblasts through regulating the TGF-β/Smad signaling pathway.

Authors:  Jin-Cheng Liu; Lei Zhou; Feng Wang; Zong-Qi Cheng; Chen Rong
Journal:  Chin J Nat Med       Date:  2018-05

9.  Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function.

Authors:  Konstantinos Drosatos; Nina M Pollak; Christine J Pol; Panagiotis Ntziachristos; Florian Willecke; Mesele-Christina Valenti; Chad M Trent; Yunying Hu; Shaodong Guo; Iannis Aifantis; Ira J Goldberg
Journal:  Circ Res       Date:  2015-11-16       Impact factor: 23.213

Review 10.  The Role of MicroRNAs in Myocardial Infarction: From Molecular Mechanism to Clinical Application.

Authors:  Teng Sun; Yan-Han Dong; Wei Du; Chun-Ying Shi; Kun Wang; Muhammad-Akram Tariq; Jian-Xun Wang; Pei-Feng Li
Journal:  Int J Mol Sci       Date:  2017-03-31       Impact factor: 6.208

View more
  3 in total

Review 1.  Krüppel-like factor (KLF)5: An emerging foe of cardiovascular health.

Authors:  Dimitra Palioura; Antigone Lazou; Konstantinos Drosatos
Journal:  J Mol Cell Cardiol       Date:  2021-10-13       Impact factor: 5.000

Review 2.  Signaling pathways and targeted therapy for myocardial infarction.

Authors:  Qing Zhang; Lu Wang; Shiqi Wang; Hongxin Cheng; Lin Xu; Gaiqin Pei; Yang Wang; Chenying Fu; Yangfu Jiang; Chengqi He; Quan Wei
Journal:  Signal Transduct Target Ther       Date:  2022-03-10

3.  CircRNA MFACR Is Upregulated in Myocardial Infarction and Downregulates miR-125b to Promote Cardiomyocyte Apoptosis Induced by Hypoxia.

Authors:  Shujuan Wang; Long Li; Weijie Deng; Minhua Jiang
Journal:  J Cardiovasc Pharmacol       Date:  2021-09-12       Impact factor: 3.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.